Efficacy and Safety of Clinical Use of Etanercept for the Treatment of Moderate-to-Severe Psoriasis in Spain: Results of a Multicentric Prospective Study at 12 Months Follow-Up

Publisher： Karger

E-ISSN： 1421-9832|225|3|220-230

ISSN： 1018-8665

Source： Dermatology, Vol.225, Iss.3, 2012-12, pp. : 220-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

By  

Dermatology, Vol. 219, Iss. 3, 2009-09 ,pp. : 239-249

Karger

Access to resources Recommend Favorite

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

By  

Dermatology, Vol. 230, Iss. 1, 2015-01 ,pp. : 46-54

Karger

Access to resources Recommend Favorite

Prospective Randomized Study on the Efficacy of Blue Light in the Treatment of Psoriasis Vulgaris

By  

Dermatology, Vol. 223, Iss. 3, 2011-11 ,pp. : 251-259

Karger

Access to resources Recommend Favorite

Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris

By  

Dermatology, Vol. 231, Iss. 1, 2015-06 ,pp. : 24-34

Karger

Access to resources Recommend Favorite

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

By  

Dermatology, Vol. 213, Iss. 4, 2006-12 ,pp. : 319-326

Karger

Access to resources Recommend Favorite